News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
FDA Expands Approval of Pfizer’s HYMPAVZI for Additional Hemophilia A and B Patient Groups
Tuesday, June 09, 2026Pfizer has received approval from the US Food and Drug Administration FDA for an expanded indication of HYMPAVZI marstacimabhncq extending its use to patients aged years and older with hemophilia
Engitix and GSK Partner to Advance New Targets for Liver Fibrosis Treatment
Tuesday, June 09, 2026Engitix has entered into a strategic research collaboration and option agreement with GSK to identify and validate novel therapeutic targets aimed at promoting liver fibrosis regression
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Friday, June 05, 2026Biogen has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy Designation to salanersen for the treatment of spinal muscular atrophy SMA
Teva launches AHZANTIVE biosimilar to Eylea across Europe
Friday, June 05, 2026Teva Pharmaceutical Industries has launched AHZANTIVE aflibercept a biosimilar to Eylea in Europe expanding its biosimilars portfolio and strengthening its presence in the ophthalmology sector
Lundbeck Partners with Cradle to Advance AI-Driven Brain Disorder Treatments
Thursday, June 04, 2026H Lundbeck AS has entered a partnership with Cradle to support the discovery and optimisation of biotherapeutics for brain disorders using artificial intelligence
Lupin and Natco Receive US FDA Approval for Eribulin Mesylate Injection
Wednesday, June 03, 2026Lupin Limited and its alliance partner Natco Pharma have received approval from the US Food and Drug Administration FDA for Natcos Abbreviated New Drug Application ANDA for Eribulin Mesylate Injection mg mL
Vertex Receives FDA Acceptance for Povetacicept Application in IgA Nephropathy
Tuesday, June 02, 2026Vertex Pharmaceuticals has announced that the US Food and Drug Administration FDA has accepted its Biologics License Application BLA for povetacicept an investigational treatment for adults with immunoglobulin A nephropathy IgAN
Haisco and Lilly Enter Research and Licensing Partnership for Innovative Medicines
Tuesday, June 02, 2026Haisco Pharmaceutical Group Co Ltd has entered into a licensing and research collaboration with Eli Lilly and Company to develop innovative medicines across multiple therapeutic areas
